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CI:	 −23.5	 to	 76.5),	 and	 53.6%	 (95%	 CI:	 −62.6	 to	 80.3)	 against	 influenza	 A(H1N1)
pdm09.
K E Y W O R D S
effectiveness,	influenza,	vaccine
1  | INTRODUCTION

















included	 in	 the	 2015	 vaccine	 in	 South	 Africa	 were	 as	 follows:	 A/
California/7/2009	 (H1N1)-	like	 virus,	 A/Switzerland/9715293/2013	
(H3N2)-	like	virus	and	B/Phuket/3073/2013-	like	virus	(Yamagata	lin-
eage).	We	aimed	 to	estimate	 trivalent	 influenza	vaccine	 (TIV)	 effec-




During	 2015,	 107	 outpatient	 practitioners	 at	 67	 practices	 in	 eight	
of	the	nine	provinces	of	South	Africa	participated	in	the	Viral	Watch	
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sentinel	 influenza	 surveillance	programme.	Patients	presenting	with	
influenza-	like	 illness	 (ILI)	 to	 participating	 practitioners	 and	 testing	







Specimens	were	 tested	 using	multiplex	 reverse	 transcription	 real-	











conditions	 collected	 were	 as	 follows:	 chronic	 pulmonary	 and	 cardiac	
disease,	immunosuppression	(including	HIV),	metabolic	disorders,	preg-
nancy	and	morbid	obesity	defined	as	a	body	mass	index	of	≥40.
The	 start	 of	 the	 influenza	 season	was	 defined	 as	 two	 consecu-
tive	weekly	influenza	detection	rates	of	≥10%,	and	the	end	as	when	
the	detection	 rate	 dropped	below	10%	 for	 two	 consecutive	weeks,	







943 specimens submitted 4 May – 13 September 
44 specimens excluded from analysis
22 date of onset unknown
13 aged <6 months/age unknown
5 did not adhere to case definion
4 vaccinated <14 days prior to onset
899 specimens included















































Pn (%) n (%) n (%)
Vaccine	receipt
Vaccinated 9	(1.9) 20	(4.7) 29	(3.2) .02
Not vaccinated 467	(98.1) 403	(95.3) 870	(96.8)
Age group
Median 32 y 33 y 32 y .04
<18 y 143	(30.0) 112	(26.5) 255	(28.4)
18-	64	y 317	(66.6) 282	(66.7) 599	(66.6)
≥65	y 16	(3.4) 29	(6.9) 45	(5.0)
Sex
Male 230	(48.3) 186	(44.0) 416	(46.3) .32
Female 242	(50.8) 235	(55.6) 477	(53.1)




288	(60.5) 160	(37.8) 448	(49.9) <.01
Mid	(weeks	25-	31) 152	(31.9) 167	(39.5) 319	(35.5)
Late	(weeks	32-	37) 36	(7.6) 96	(22.7) 132	(14.7)
Region








None 404	(84.9) 368	(87.0) 772	(85.9) .37
Yes 72	(15.1) 55	(13.0) 127	(14.1)
Interval	between	onset	and	sampling	(days)
0-	3	d 440	(92.4) 365	(86.3) 805	(89.5) .03




















pdm09	which	 accounted	 for	 242/476	 (50.8%)	 of	 the	 total	 influenza	
subtypes	 detected,	 followed	 by	 influenza	A(H3N2)	which	 accounted	
for	182/476	(38.2%)	of	detections	with	the	remaining	detections	being	






and	 477	 (53.1%)	 patients	were	 female.	 Fifty	 per	 cent	 (448/899)	 of	
specimens	were	collected	in	the	early	weeks	of	the	season,	although	
this	proportion	was	higher	 [288/476	 (60.5%)]	 for	 cases.	The	major-

















fluenza	A(H1N1)pdm09,	65.9%	 (95%	CI:	−53.9	 to	92.4)	against	 in-
fluenza	A(H3N2)	 and	 33.0%	 (95%	CI:	 −207.8	 to	 85.4)	 against	 any	
lineage	of	influenza	B.	When	restricted	to	specimens	collected	within	



















n/N (%) n/N (%) n/N (%)
Total 9/476	(1.9) 20/423	(4.7) 29/899	(3.2) 61.2	(13.8,	82.5)
UMCa 3/72	(4.2) 3/55	(5.5) 6/127	(4.7) 24.6	(−288.6,	85.4)
No	UMC 6/405	(1.5) 17/368	(4.6) 23/772	(3.0) 68.9	(20.2,	87.9)
<18 y 0/143	(0) 1/112	(0.9) 1/255	(0.4)
18-	64	y 7/317	(2.2) 18/282	(6.4) 25/599	(4.2) 66.9	(19.5,	86.4)
≥65	y 2/16	(12.5) 1/29	(3.4) 3/45	(6.7) −300.0	(−4699.1,	66.7)
Central	Plateau 4/211	(1.9) 14/221	(6.3) 18/432	(4.2) 71.4	(11.7,	90.7)
NE	Subtropical 4/70	(5.7) 1/72	(1.4) 8/142	(5.6) −330.3	(−3849.2,	53.1)
Southern	coastal 1/195	(0.5) 5/130	(3.8) 6/325	(1.8) 87.1	(−11.6,	85.1)
Season:	early 1/288	(0.3) 3/160	(1.9) 4/448	(0.9) 81.7	(−76.8,	98.1)
Season:	mid 7/152	(4.6) 11/167	(6.6) 18/319	(5.6) 31.5	(−81.4,	74.2)
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A(H3N2)	increased,	but	decreased	for	influenza	A(H1N1)pdm09	and	
influenza	B.	When	restricted	to	the	weeks	that	the	type	or	subtype	


















vaccine	was	46%	effective	 in	preventing	 laboratory-	confirmed	 in-










n/N (%) n/N (%) n/N (%)
All specimens
Any	influenza 9/476	(1.9) 20/423	(4.7) 29/899	(3.2) 46.2	(−23.5,	76.5)
A(H1N1)pdm09 5/242	(2.1) 20/423	(4.7) 25/665	(3.8) 53.5	(−62.6,	80.3)
A(H3N2) 2/182	(1.1) 20/423	(4.7) 22/605	(3.6) 65.9	(−53.9,	92.4)
B 2/57	(3.5) 20/423	(4.7) 22/480	(4.6) 33.0	(−207.8,	85.4)
Specimens	collected	≤3	d	after	onset	of	symptoms
Any	influenza 8/440	(1.8) 18/365	(4.9) 26/805	(3.2) 52.2	(−15.0,	80.1)
A(H1N1)pdm09 5/225	(2.2) 18/365	(4.9) 23/590	(3.9) 43.9	(−63.1,	80.7)
A(H3N2) 1/165	(0.6) 18/365	(4.9) 19/530	(3.6) 82.1	(−39.8,	77.1)
B 2/55	(3.6) 18/365	(4.9) 20/420	(4.8) 32.0	(−216.4,	85.4)
Only	weeks	when	type/subtype	was	circulating
A(H1N1)pdm09 5/242	(2.1) 16/378	(4.2) 21/620	(3.4) 37.2	(−85.9,	78.8)
A(H3N2) 2/182	(1.1) 13/341	(3.8) 15/523	(2.9) 61.3	(−79.4,	91.6)











n/N (%) n/N (%) n/N (%)
All specimens
Any	influenza 7/317	(2.2) 18/282	(6.4) 25/599	(4.2) 54.4	(−14.1,	81.8)
A(H1N1)pdm09 5/181	(2.8) 18/282	(6.4) 23/463	(5.0) 37.3	(−93.6,	77.7)
B 2/34	(5.9) 18/282	(6.4) 20/316	(6.3) 28.2	(−236.5,	84.7)
Specimens	collected	≤3	d	after	onset	of	symptoms
Any	influenza 7/302	(2.3) 16/263	(6.1) 23/565	(4.1) 53.5	(−18.4,	81.8)
A(H1N1)pdm09 5/182	(2.7) 16/263	(6.1) 21/445	(4.7) 34.5	(−96.1,	78.1)
B 2/37	(5.4) 16/263	(6.1) 18/300	(6.0) 25.4	(−255.3,	84.3)
Only	weeks	when	type/subtype	was	circulating
A(H1N1)pdm09 5/181	(2.8) 14/239	(5.9) 19/420	(4.5) 25.7	(−127.0,	75.7)
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The	influenza	season	started	early	 in	week	16	(week	starting	13	
April).	Due	to	technical	difficulties,	the	vaccine	was	only	available	from	
late	April	 onwards	which	may	 have	 compounded	 the	 low	 influenza	
vaccine	coverage	of	3%,	although	overall	vaccine	coverage	in	previous	
years	in	the	same	population	has	ranged	from	1.8%	in	2012	to	5.1%	
in 2006.2-4	 In	 the	 early	 part	 of	 the	 season,	 four	 patients	 had	 to	 be	
excluded	from	the	analysis	due	to	having	received	 influenza	vaccine	
<14	days	prior	to	onset	of	symptoms.
Amongst	 other	 southern	 hemisphere	 countries,	 New	 Zealand	
reported	preliminary	overall	VE	of	36%	against	ILI,	and	a	VE	of	50%	
against	hospitalisation	in	a	season	where	A(H3N2)	predominated.8 In 







sample	 size.	 Previous	 studies	 have	 shown	 that	 although	 antibody	
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